Abstract
A 35-year old woman developed Burkitt's lymphoma and was treated with rituximab and CHOP therapy early during pregnancy. Monitoring of rituximab concentrations and B-cell counts in the child revealed a transient complete B-cell depletion associated with high rituximab cord blood concentrations. B-cell recovery was fast, showing a regular immunophenotype without loss of CD20 antigen, no functional deficits and adequate vaccination IgG titers.
MeSH terms
-
Adult
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal / blood
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Burkitt Lymphoma / blood
-
Burkitt Lymphoma / drug therapy
-
Child, Preschool
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Fetal Blood / drug effects
-
Humans
-
Infant, Newborn / blood*
-
Prednisone / administration & dosage
-
Pregnancy
-
Prenatal Exposure Delayed Effects / blood*
-
Rituximab
-
Vincristine / administration & dosage
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone